#USA #Class Action #Philadelphia #Berger Montague #ADMA Biologics

Class Action Against ADMA Biologics: What You Need to Know

In a significant development for investors, the national law firm Berger Montague has initiated a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA). This action comes in light of serious allegations regarding the company's financial reporting practices, which seem to suggest potential misconduct over a defined period. The primary aim of this legal initiative is to seek justice for shareholders who acquired ADMA shares during a critical timeframe from August 9, 2024, to March 25, 2026.

Overview of the Allegations

The core of the allegations stems from a report published by Culper Research, which accused ADMA of engaging in manipulative practices to inflate its revenue figures. The report claims that the company facilitated an artificial increase in its revenue by encouraging a distributor to excessively stock its flagship product, ASCENIV, a liquid immune globulin used to treat Primary Humoral Immunodeficiency. The practice, termed 'channel stuffing,' allegedly allowed ADMA to report a 20% revenue growth for 2025, despite actual revenue trends showing a possible decline of 3% if such practices had not been employed.

This severe accusation, if proven true, paints a troubling picture of deceptive practices aimed at misleading investors about the financial health of ADMA. Following the publication of this report, ADMA's stock price faced a notable decline, losing $2.26 per share on March 24, 2026, followed by a subsequent drop of $1.70 per share the next day. These sharp decreases underscore the market's reaction to the unsettling news regarding the company's financial integrity.

The Class Action Lawsuit

Berger Montague is currently representing investors in this class action, and the firm has notified eligible shareholders about their rights to seek representation by applying to be lead plaintiffs. Interested parties have until August 10, 2026, to assert their claims. Berger Montague's approach aligns with its long-standing reputation in handling complex civil litigation and class actions, highlighting its commitment to holding corporations accountable for unethical practices.

About ADMA Biologics

ADMA Biologics operates from Ramsey, NJ, and focuses on specialty biologics geared towards treating immune deficiencies and infectious diseases. The company’s flagship product, ASCENIV, is vital for a segment of patients relying on immunoglobulin therapies. Given the current allegations, stakeholders are keen to understand the strategy ADMA will adopt moving forward and how it plans to manage shareholder relations amid this turbulence.

Importance of Investor Vigilance

For investors, this unfolding situation serves as a critical reminder of the importance of due diligence and vigilance when dealing with publicly traded entities. The fallouts from financial misconduct can be severe, not just in terms of financial loss but also regarding reputational damage and potential regulatory ramifications. This incident will likely lead to increased scrutiny not only for ADMA but also across the biopharmaceutical sector, creating a ripple effect as investors reassess their risks.

Conclusion

As this class action progresses, it will be crucial for investors to stay informed about the developments. The outcome could potentially set precedents for corporate accountability in the realm of financial disclosures and investor protections. Shareholders affected by the alleged misconduct can reach out to Berger Montague for more information on the class action initiative and what steps they should take to assert their rights. The legal landscape surrounding securities fraud is intricate and often favors meticulous and informed participants.

Contact Information

For further inquiries, affected investors are urged to get in touch with Andrew Abramowitz or Caitlin Adorni at Berger Montague, ensuring they understand their legal standing and potential avenues for recourse. The unfolding of this case could very well illuminate the practices within the industry and inspire a call for enhanced transparency from biopharmaceutical companies moving forward.